Molecular Designs Unveils Innovative Microbiota Panel for Urogenital Pathogens and Resistance Detection
Molecular Designs, a prominent name in the field of molecular infectious disease assays, has recently introduced its latest product, the Urogenital Microbiota with ABX 53 Simplicity Panel ™. Designed specifically for research purposes, this cutting-edge panel employs a multiplex PCR-based approach to efficiently identify a variety of urinary pathogens and antibiotic resistance genes. This innovative tool focuses on providing rapid, accurate, and streamlined results that are crucial for both researchers and healthcare laboratories alike.
With the escalating concerns over antibiotic resistance, the Urogenital Microbiota Panel steps in as a timely solution. It offers comprehensive detection capabilities, identifying a total of 28 different urinary targets, including 20 bacterial, seven fungal, and one protozoan organism, along with 25 vital antibiotic resistance markers. This extensive panel of targets ensures that laboratories have the necessary data to combat drug-resistant microbes effectively.
One of the standout features of the Urogenital Microbiota Panel is its ability to deliver same-day results—a significant improvement over traditional methods that may require extensive waiting periods. The streamlined workflow not only reduces the potential for errors during the testing process but also saves precious time for laboratory personnel. The product is engineered with a lab-friendly format, available in 96 and 384-well configurations, which eliminates waste and enhances operational efficiency.
Molecular Designs’ CEO, Michael Clark, emphasized the necessity of such innovations in today’s research landscape: “With drug resistance on the rise, labs are being asked to do more with fewer resources. This panel was built to help them keep pace by providing comprehensive answers with a workflow that fits seamlessly into today's research lab environment.” Indeed, as laboratories face increasing pressure to deliver results while managing limited resources, tools like the Urogenital Microbiota Panel are crucial.
Dr. Greer Massey, Chief Scientific Officer at Molecular Designs, highlighted the significance of addressing antimicrobial resistance: “Antimicrobial resistance isn't just a lab challenge, it's one of the most pressing threats in medicine today. By combining urogenital target detection with resistance gene profiling in a single panel, this product gives researchers the insight they need to track emerging threats and make more informed decisions, faster.”
The design of the Urogenital Microbiota Panel also positions it as an excellent asset for research labs aiming to investigate microbial profiles and resistance mechanisms across diverse urogenital samples. As global resistance rates continue to climb, having timely and reliable testing tools becomes essential for laboratories striving to stay ahead in microbiological research.
More details on the Urogenital Microbiota with ABX 53 Simplicity Panel ™ can be found on the company's official website, www.moleculardesigns.com. It’s important to note that the product is intended exclusively for research use and is not approved for diagnostic applications.
About Molecular Designs:
Founded by a team of physicians, Molecular Designs is committed to enhancing the accessibility and cost-effectiveness of molecular technologies. Their portfolio includes multiple multiplex PCR-based panels produced under stringent GMP and ISO 13485:2016 quality standards. For detailed insights and updates, visit their website or follow them on LinkedIn.
With the escalating concerns over antibiotic resistance, the Urogenital Microbiota Panel steps in as a timely solution. It offers comprehensive detection capabilities, identifying a total of 28 different urinary targets, including 20 bacterial, seven fungal, and one protozoan organism, along with 25 vital antibiotic resistance markers. This extensive panel of targets ensures that laboratories have the necessary data to combat drug-resistant microbes effectively.
One of the standout features of the Urogenital Microbiota Panel is its ability to deliver same-day results—a significant improvement over traditional methods that may require extensive waiting periods. The streamlined workflow not only reduces the potential for errors during the testing process but also saves precious time for laboratory personnel. The product is engineered with a lab-friendly format, available in 96 and 384-well configurations, which eliminates waste and enhances operational efficiency.
Molecular Designs’ CEO, Michael Clark, emphasized the necessity of such innovations in today’s research landscape: “With drug resistance on the rise, labs are being asked to do more with fewer resources. This panel was built to help them keep pace by providing comprehensive answers with a workflow that fits seamlessly into today's research lab environment.” Indeed, as laboratories face increasing pressure to deliver results while managing limited resources, tools like the Urogenital Microbiota Panel are crucial.
Dr. Greer Massey, Chief Scientific Officer at Molecular Designs, highlighted the significance of addressing antimicrobial resistance: “Antimicrobial resistance isn't just a lab challenge, it's one of the most pressing threats in medicine today. By combining urogenital target detection with resistance gene profiling in a single panel, this product gives researchers the insight they need to track emerging threats and make more informed decisions, faster.”
The design of the Urogenital Microbiota Panel also positions it as an excellent asset for research labs aiming to investigate microbial profiles and resistance mechanisms across diverse urogenital samples. As global resistance rates continue to climb, having timely and reliable testing tools becomes essential for laboratories striving to stay ahead in microbiological research.
More details on the Urogenital Microbiota with ABX 53 Simplicity Panel ™ can be found on the company's official website, www.moleculardesigns.com. It’s important to note that the product is intended exclusively for research use and is not approved for diagnostic applications.
About Molecular Designs:
Founded by a team of physicians, Molecular Designs is committed to enhancing the accessibility and cost-effectiveness of molecular technologies. Their portfolio includes multiple multiplex PCR-based panels produced under stringent GMP and ISO 13485:2016 quality standards. For detailed insights and updates, visit their website or follow them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.